Annovis Bio, Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at Combined offering price of $1.90 per Share and accompanying Warrant, gross proceeds ~$10 million (effective 2026-04-09).
“On April 9, 2026, Annovis Bio, Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of April 9, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering (the “Offering”) (i) an aggregate of 5,263,156 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase an aggregate of 5,263,156 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”).”
Andrew Walsh was appointed as Principal Financial Officer at Annovis Bio, Inc..
“On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.”
Maria Maccecchini was appointed as Principal Financial Officer on an interim basis at Annovis Bio, Inc..
“Maria Maccecchini will continue to serve as principal financial officer on an interim basis.”
William Fricker departed as Interim Chief Financial Officer at Annovis Bio, Inc..
“On March 27, 2025, by mutual agreement, Mr. Fricker will no longer serve as interim Chief Financial Officer.”
Earnings Releases
Annovis Bio, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update.”
Maria Maccecchini was appointed as interim principal financial officer at Annovis Bio, Inc..
“On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.”
Henry Hagopian departed as Chief Financial Officer at Annovis Bio, Inc..
“Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.”
Material Agreements
Annovis Bio, Inc. entered into Common Stock Purchase Agreement with the Equity Line investor (the "ELOC Purchaser") valued at up to 2,051,428 shares (effective 2024-04-25).
“On April 25, 2024, Annovis Bio, Inc., a Delaware corporation (the “Company”), entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with the Equity Line investor (the “ELOC Purchaser”), whereby the Company may offer and sell, from time to time at its sole discretion, and whereby the ELOC Purchaser has committed to purchase, up to 2,051,428 shares of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) (but subject to the limitations described below).”
Earnings Releases
Annovis Bio, Inc. reported fourth quarter and full year 2023 results: net income $22.2 million.
“today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.”
Material Agreements
Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2024-03-21).
“On March 21, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).”
Material Agreements
Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds of $1,025,000 (effective 2024-03-15).
“On March 15, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.